Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21591606 | 0.78 | — | — | |
| Formic Acid SCHEMBL28988550 | 0.78 | KDM4E (0.39) | ERN1KDM4EALDH1A1USP2HPGD | |
| SCHEMBL3869526 | 0.77 | CTSL (0.32) | — | |
| SCHEMBL1585113 | 0.77 | S1PR4 (0.32) | — | |
| SCHEMBL11918448 | 0.75 | ALDH1A1 (0.57) | KDM4EALDH1A1USP2HPGDHSD17B10 | |
| SCHEMBL3645829 | 0.74 | KDM4E (0.33) | KDM4EALDH1A1USP2HPGDHSD17B10 | |
| SCHEMBL21591717 | 0.70 | — | — | |
| SCHEMBL15990229 | 0.69 | ERN1 (0.41) | ERN1KDM4EL3MBTL1 | |
| SCHEMBL23089226 | 0.69 | KDM4E (0.42) | KDM4EALDH1A1USP2HPGDHSD17B10 | |
| SCHEMBL29814600 | 0.69 | KDM4E (0.42) | KDM4EALDH1A1USP2HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227328-B2 | Heterocyclic compound and pharmaceutical composition comprising same | BEYONDBIO INC. (KR) | 2019-03-12 | — | — | US | disclosed |
| US-20180273510-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2018-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227328-B2 | Heterocyclic compound and pharmaceutical composition comprising same | CDK5, CDK1, CDK4 | ERN1 1845/4885KDM4E 564/4885ALDH1A1 2920/4885 |
| US-20180273510-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CDK5, CDK1, CDK4 | ERN1 1845/4885KDM4E 564/4885ALDH1A1 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.